GBM radiosensitizers: dead in the water…or just the beginning?


Journal Article (Review)

The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control. Unfortunately, decades of clinical trials testing a wide range of novel therapeutic approaches have failed to yield any clinically viable radiosensitizers. However, many of  the previous radiosensitizing strategies were not based on clear pre-clinical evidence, and in many cases blood-barrier penetration was not considered. Furthermore, DNA repair inhibitors have only recenly arrived in the clinic, and likely represent potent agents for glioma radiosensitization. Here, we present recent progress in the use of small molecule DNA damage response inhibitors as GBM radiosensitizers. In addition, we discuss the latest progress in targeting hypoxia and oxidative stress for GBM radiosensitization.

Full Text

Duke Authors

Cited Authors

  • Bindra, RS; Chalmers, AJ; Evans, S; Dewhirst, M

Published Date

  • September 2017

Published In

Volume / Issue

  • 134 / 3

Start / End Page

  • 513 - 521

PubMed ID

  • 28762004

Pubmed Central ID

  • 28762004

Electronic International Standard Serial Number (EISSN)

  • 1573-7373

Digital Object Identifier (DOI)

  • 10.1007/s11060-017-2427-7


  • eng

Conference Location

  • United States